Law360, New York (April 06, 2009, 12:00 AM ET) -- Biovail Corp. has become the latest generics maker to ask a court to invalidate or rule unenforceable two patents for Seroquel XR — AstraZeneca Pharmaceuticals LP's popular treatment for bipolar disorder and schizophrenia — filing counterclaims that accuse the pharmaceutical giant of inequitable conduct.
The counterclaims, filed Friday in the U.S. District Court for the District of New Jersey, argue that one of the patents is unenforceable because the patent applicants failed to share pertinent information with the U.S. Patent and Trademark Office and tried to...
Biovail Fires Back At AstraZeneca In Seroquel IP Suit
To view the full article, take a free trial now.
